No biggie.

Yessir! The market took it all wrong, believing RMAT was abandoned. Nope, the pause button is different from the stop button for a reason!

Not sure what all has happened to this company as of late, but the flip from .006 paid off.

I no longer look at these guys as a salient business entity, rather a chart play to flip on. Only ways to reestablish my confidence in them would be through MM sponsorship and a tangible plan to sell their products and best the competition. Growlife would need a production line of their own to establish a brand, but seems far from their once popular greners.com site.

If it goes back to .006 or below, I'll probably play again.

Waow! Feeling good I scooped up when it took that dip.

So true. I took a break checking it on Friday, only to come back and find that they had quite the recovery.

Something about that with this company. When I take my eyes off the stock, good things happen.

I got rid of a more risky position and put it here.

Just did! Anything below 3 looks good for picking up right now.

Now I can relax and get back to the day job

Half tempted to add more here

Health makes wealth.

In this case, a company on the forefront of advanced medical treatment.

With one of the most renowned in the field working for them. Said it before and I'll say it again - Comella is a huge factor for my investment here.

Double what I usually see in volume and the sky hasn't fallen yet.

Not as bad as expected considering this morning. Might be some challenging days, but RSI sure is low enough to warrant a ride back up.

Got some cheapies and a bit of swing back in your step I see!

Agreed that it's all on the company to restore confidence. A disservice was done to the way RMAT activity was communicated. We are fortunate that the financials proved they've got their money where their mouth is.

They're making it up to us day by day, and with glowing financials as a great first step.

Transferring funds from the impatient to the patient.

Let them try to run it down, use all their might and scare tactics available. A company like this always maintains the buoyancy to float back to the top.

I'm all for it. Another buying opportunity sounds appealing.

Growlife showing a heartbeat again after all these years. Picked up some at historic lows and couldn't be happier.

6's were a great choice. Like that we're seeing 7's!

Why would they mention RMAT when it was previously addressed?

Good to see they're compensating Their star players well considering the value brought in by the higher revs that those individuals are responsible for. Well enough to earn bonuses! Bravo.

Everyone looking at the same info I am?

Because it's been up, down, and up again.

People buy low, sell high, buy low again and enjoy the ride.

And some are still calling this some sort of trading anomaly?

Long term strength on the report and those taking advantage of a pop shouldn't be confused.

Turns out focusing revenue is a good thing!

Not necessarily. You can short whatever you like (depending on your broker/platform). The risk comes when you bet wrong and owe more than you hold on the account. If someone is shorting a stock that rockets upwards, it is possible to drain the account to a point where money is owed. Buying and holding just means you could lose it all, but not owe.

You don't want to short something you can't cover, but stocks fail in the OTC all the time. DRYS has been a great example of that historically. R/S then short into the ground like clockwork.

On the other side, what I'm seeing on USRM chart is a near term historic low in price. You'll see about 6 months ago that they were trading at next to nothing, but as of the last 3 months have added and are holding value. The pop to .17 was clearly artificial, but they'd REALLY have to throw the game to go much lower than this with the current interest in stem cell tech. That said, the company still needs to provide investors with knowledge that USRM is doing well on the business side and making money. Severe losses would be unacceptable, and it appears that focusing profit was their big goal in dropping RMAT pursuit for the time being.

They need to innovate, advance AND profit. No point in being cutting edge if you can't make a buck.

Being realistic is fine. Being short or looking for a lower entry point is just as obvious as those who bought in and want the pps to rise.

An easy game we all play really. It either goes up or down.

Snap needs to lose a little more value yet, but years down will be fine.

Lots of activity on board and in stock. Starting to heat up again!

Loving the chart even more now that it sees 4's.

LOL back up we go.

Picked up some shares at support. Good risk to take.

Chart looking pretty good right now!

LOL sure is heating up around here.

Know what you mean. Bought the dips and holding. Depending on what happens near future, they may warrant a bigger investment from me.

Until then, there are plenty of others to make money with.

Still USRM strong.

Pretty good loading zone. So long as this doesn't dip down or go below 3's

What's your target entry price?

Set stop losses folks. You don't have to keep the pain of loss that some loud mouth on twitter talked you into.

People like that aren't out to help, just make a buck at your expense.

Probably back to the teens. A lot of people said even higher, but I try to look at it realistically and it went up to around .17-.18 with what looked to be baked in expectations of RMAT approval earlier in summer.

LOL what a shit show. Lessons in why people shouldn't follow 'twitter personalities'

Yah, I'm on board with this.

If the 10Q comes out and it turns out the CEO was BSing, then I'll be the first to lead the angry mob.

But if their report isn't as glowing as he is leading on, he'll be in a world of regret.

I don't think he would sacrifice the whole thing in hopes for a few cents, just the same way Comella wouldn't sacrifice her reputation as a top Stem Cell Innovator.

Wow, new lows!

Great to see everyone in better spirits.

The next release of that information sure will be make or break for them. Proving legitimacy, or spinning their wheels?

I'll admit, if Comella was not a part of this team - then I'd be wary. I couldn't see someone sacrificing their scientific reputation and career for a company that can't deliver.

That said, if they reveal increasing earnings - that's the hallmark of a good investment.

Lots of gloom and doom for a relatively boring trading day.

USRM: Kristin Comella

Top Stem Cell Innovator.

I added in the 3's and right at 4 as well.

This company is undervalued and oversold, that much is CLEAR!

Let's just keep it under .04 for another day or so and I'll take any shares off the table in the 3's.

We're here because this company holds value. Even the bashers are here because of that very reason. USRM provides a service that is increasingly sought after in a relatively recent field of medical advancement. Stem cell treatments used to be vilified, and the industry has come so far in the last several years.

If you went all in at higher levels, then it's a tough position to be in - just as it is with any ticker you buy into on a high side. It didn't seem like those levels would be highs at the time, but life will throw mountains in front of your road to el dorado. Seen it here, seen it with pot stocks, and all over the OTC. Chances are high that down that road, you'll be collecting your gains while people playing with short term goals will still be stuck scrambling for a piece of the pie.

I'm strangely hoping that your worries become reality since I'm expecting funds to clear shortly.

That would be a tremendous level to buy more. Hopefully they hang at these levels at least, but you never know! I've seen it tank at the beginning of the day and end at a strong green.

Just one or two more days for that powder to get through, cross your fingers!

They just need to share a strong direction that will accommodate government, profits and in turn - the shareholders.

For a valid company in this field and their medical benefit, these are very cheap prices.

If they lose shareholder confidence and botch the company plans, then it won't matter because buyers won't be interested. Comella is a gem, but they need exposure.